{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-025156","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2023-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.294424+00:00","generated_at":"2026-06-13T05:43:32.399031+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Abbott Q2 2023: Sales $10B, adjusted EPS $1.08; underlying base organic growth 11.5%","bullets":["Q2 GAAP diluted EPS $0.78; adjusted diluted EPS $1.08; revenue $9,978M, down 11.4% reported (COVID testing decline).","Underlying base business organic sales growth 11.5% led by Medical Devices (+14.2% organic) and Nutrition (+9.9% organic).","Full-year 2023 adjusted EPS guidance reaffirmed at $4.30-$4.50; COVID testing sales forecast $1.3B.","FreeStyle Libre sales $1.3B, up 24.7% organic; new product approvals: TactiFlex, AVEIR dual-chamber pacemaker.","Quarterly dividend $0.51/share declared, payable Aug 15, 2023; 51 consecutive years of increases."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-025156","json":"https://secwatch.observer/filing/0001628280-23-025156.json","markdown":"https://secwatch.observer/filing/0001628280-23-025156.md","text":"https://secwatch.observer/filing/0001628280-23-025156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000162828023025156/0001628280-23-025156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000162828023025156/abt-20230720.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T05:43:32.399031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77cd430b39502b2abfcb300ff13600596e5c2a18","claim":"ABBOTT LABORATORIES reported second quarter 2023 results: revenue $10.0 billion, EPS $0.78.","evidence_excerpt":"in accordance with GAAP. --- EX-99.1 (EX-99.1) --- 9.1 News Release Abbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business – Sales of $10.0 billion driven by strong underlying base business performance – Reported sales decreased 11.4 percent due to anticipated decline in COVID-19 testing-related sales versus prior year –","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828023025156/0001628280-23-025156-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Revenue","value":"$10.0 billion"},{"label":"EPS","value":"$0.78"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}